Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -85.65% is 72% below its 3-year average of -49.66%, near the low end of its 3-year range (-85.65%–-18.28%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.14% below its 12-month average of -71.89%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -85.65%.
RETURN ON EQUITY (ROE)
-85.65%
RETURN ON EQUITY (ROE) AVG TTM
-71.89%
RETURN ON EQUITY (ROE) AVG 3Y
-54.13%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.14%
CURRENT VS 3Y AVG
-58.21%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.17%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
-124.38%
vs the sector median at left
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$84.75M
Return on Equity (ROE)
-85.65%
TTM Avg
-71.89%
3Y Avg
-54.13%
5Y Avg
N/A
Market Cap
$84.70M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
Market Cap
$84.00M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$83.96M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
Market Cap
$83.49M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$86.69M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.86M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$88.21M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
Market Cap
$81.22M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $84.75M | -85.65% | -71.89% | -54.13% | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A | 1.45% | 25.22% | -14.52% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -309.44% | -515.53% | -464.77% | -329.14% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | -50.80% | -124.86% | -88.30% | -60.21% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 45.93% | 16.96% | -19.36% | -13.87% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -150.95% | -77.89% | -62.90% | -47.80% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.51% | -5.84% | -10.75% | -7.81% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | -114.06% | -50.52% | -45.18% | -45.18% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -1542.57% | -254.55% | -187.52% | -143.69% |
ROE
-85.6%
ROA
-74.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -85.65% |
| 2026-03-31 | -80.90% |
| 2025-12-31 | -69.24% |
| 2025-09-30 | -63.57% |
| 2025-06-30 | -60.09% |
| 2025-03-31 | -52.22% |
| 2024-12-31 | -45.57% |
| 2024-09-30 | -39.10% |
| 2024-06-30 | -31.94% |
| 2024-03-31 | -59.38% |
| 2023-12-31 | -49.83% |
| 2023-09-30 | -36.24% |
| 2023-06-30 | -30.03% |
| 2023-03-31 | -22.87% |
| 2022-12-31 | -18.28% |
